Abstract:Abstract Introduction Tumor necrosis factor related apoptosis inducing ligand (TRAIL) can induce the apoptosis of many human leukemia cells while sparing of normal cells, but its resistance is also universal. Our previous study on apoptosis of t(8;21) positive acute myeloid leukemia cell line Kasumi-1 induced by rhTRAIL showed that the survival rate no longer decreased significantly when rsTRAIL reached a certain concentration which implied Kasumi-1 cells might have a resistant tendency to TRAIL. Then, we established a TRAIL-resistant Kasumi-1 cell line (Kasumi-1 TR) by intermittently escalating rsTRAIL concentration in culture media, and compared the mRNA expression profile with the original Kasumi-1 cell line by using Affymetrix Human Genome U133 Plus 2.0 Array. Methods Kasumi-1 TR cell line was established by intermittently treated Kasumi-1 cells with progressively escalating rsTRAIL concentration. Proliferation of leukemia cells were measured by CCK-8 assay, and rsTRAIL IC50 of cells and resistance index were calculated according to proliferation of cells treated with rsTRAIL at different concentrations. TRAIL and TRAIL receptors 1-4 on cells surface were detected by flow cytometry. Expression profiles of Kasumi-1 cells and Kasumi-1 TR cells were analyzed by Affymetrix Human Genome U133 Plus 2.0 Array to identify differentially expressed genes, and the search of genes possibly related with TRAIL-resistance were using by GO functional analysis and pathway enrichment analysis. Results 1) Kasumi-1 TR cells proliferation was faster than that of Kasumi-1 cells(Fig 1A); 2) IC50 of 24 hours for Kasumi-1 cells was 756.833ng/ml (logIC50 2.879 ± 0.148), IC50 of 24 hours for Kasumi-1 TR cells was 1634646.005ng/ ml (logIC50 6.213 ± 0.637), the RI of 24h was 2159 (Fig 1B); IC50 of 48 hours for Kasumi-1 cells was 345.390ng/ml (logIC50 2.538 ± 0.153), IC50 of 48 hours for Kasumi-1 TR cells was 33642.641ng/ml (logIC50 is 4.257 ± 0.317), the RI for 48h was 97 (Fig 1C); 3) Cell surface expression of TRAIL and its receptors 1-4 had no difference between two cell lines(Fig 1D). 4) There were 1537 genes up regulated by more than 2 times while 487 genes down regulated by more than 2 times in Kasumi-1 TR cells compared with the original Kasumi-1 cells (Fig 1E). Of which BCL-2 family antiapoptotic gene BCL2 is increased by 3.153 times and BCL2A1 increased by 18.23 times, IFNAR1 involved in JAK/STAT pathway increased by 12.841 times and TRAIL death receptor TNFRSF10A down regulated by 3.256 times(Fig 1F). Conclusions: The Kasumi-1 cell line with rsTRAIL resistance (Kasumi-1 TR) is established, and its resistance may be associated with the up expression of BCL2, BCL2A1, IFNAR1 and down regulated expression of DR4. Acknowledgment This work was supported by grants from NSFC (30672415) and STCSM (054119528). Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Absence of Death Receptor Translocation into Lipid Rafts in Acquired TRAIL-resistant NSCLC Cells.

Molecular Mechanisms of Resistance to TRAIL-induced Apoptosis in Tumor

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Redistribution of DR4 and DR5 in Lipid Rafts Accounts for the Sensitivity to TRAIL in NSCLC Cells

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

Β-Catenin Decreases Acquired TRAIL Resistance in Non-Small-cell Lung Cancer Cells by Regulating the Redistribution of Death Receptors.

Novel Molecular Regulators of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis in NSCLC Cells

Oxaliplatin Resistance in Colorectal Cancer Enhances TRAIL Sensitivity Via Death Receptor 4 Upregulation and Lipid Raft Localization

Accelerated Degradation of Caspase-8 Protein Correlates with TRAIL Resistance in a DLD1 Human Colon Cancer Cell Line.

Akt-Mediated Eminent Expression of C-Flip and Mcl-1 Confers Acquired Resistance to Trail-Induced Cytotoxicity to Lung Cancer Cells

Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells

Inducible Resistance Of Tumor Cells To Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2-Mediated Apoptosis By Generation Of A Blockade At The Death Domain Function

LiCl Increases Drug Sensitivity of TRAIL on Acquired TRAIL-Resistant Human Lung Cancer Cell H460R

Brd4 Inhibition Promotes Trail-Induced Apoptosis By Suppressing The Transcriptional Activity Of Nf-Kappa B In Nsclc

Overcoming acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand by Bcl-XL small interfering RNA in human colon cancer

Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps

Establishment of Trail-Resistance Kasumi-1 Cell Line and the Analysis of It Different Mrna Expression Profile with the Original Kasumi-1 Cell Line

Cytotoxicity and Radiosensitization Effect of TRA-8 on Radioresistant Human Larynx Squamous Carcinoma Cells.

Over Expression of BCL2 and Low Expression of Caspase 8 Related to TRAIL Resistance in Brain Cancer Stem Cells.

Effects of recombinant human tumor-necrosis factor related to apoptosis inducing ligand protein on apoptosis of human lung adenocarcinoma cell line resistant to cisplatin]

Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL